These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 30193804

  • 1. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
    Valnet-Rabier MB, Marcucci C, Limat S, Davani S, Aubin F, Nerich V.
    Therapie; 2019 Jun; 74(3):355-367. PubMed ID: 30193804
    [Abstract] [Full Text] [Related]

  • 2. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.
    Lancet; 2017 Oct 21; 390(10105):1853-1862. PubMed ID: 28822576
    [Abstract] [Full Text] [Related]

  • 3. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 21; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 4. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
    Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, Rebersek M.
    Radiol Oncol; 2020 Jan 19; 54(1):119-127. PubMed ID: 31955148
    [Abstract] [Full Text] [Related]

  • 5. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 19; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
    Sattar J, Kartolo A, Hopman WM, Lakoff JM, Baetz T.
    J Geriatr Oncol; 2019 May 19; 10(3):411-414. PubMed ID: 30104155
    [Abstract] [Full Text] [Related]

  • 7. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
    Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.
    J Cutan Pathol; 2018 Jul 19; 45(7):504-507. PubMed ID: 29633300
    [Abstract] [Full Text] [Related]

  • 8. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F.
    J Oncol Pharm Pract; 2017 Dec 19; 23(8):620-624. PubMed ID: 27590328
    [Abstract] [Full Text] [Related]

  • 9. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
    Perier-Muzet M, Gatt E, Péron J, Falandry C, Amini-Adlé M, Thomas L, Dalle S, Boespflug A.
    JAMA Dermatol; 2018 Jan 01; 154(1):82-87. PubMed ID: 29214290
    [Abstract] [Full Text] [Related]

  • 10. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
    Finger PT, Pavlick AC.
    J Immunother Cancer; 2019 Mar 25; 7(1):83. PubMed ID: 30909967
    [Abstract] [Full Text] [Related]

  • 11. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.
    JAMA; 2016 Apr 19; 315(15):1600-9. PubMed ID: 27092830
    [Abstract] [Full Text] [Related]

  • 12. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P, Tang R, Luo M.
    Int Immunopharmacol; 2020 Jan 19; 78():106050. PubMed ID: 31812724
    [Abstract] [Full Text] [Related]

  • 13. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK, Watson DE.
    Pharmacotherapy; 2017 Nov 19; 37(11):1383-1390. PubMed ID: 28950039
    [Abstract] [Full Text] [Related]

  • 14. Safety of immune checkpoint inhibitors in Chinese patients with melanoma.
    Wen X, Wang Y, Ding Y, Li D, Li J, Guo Y, Peng R, Zhao J, Zhang X, Zhang XS.
    Melanoma Res; 2016 Jun 19; 26(3):284-9. PubMed ID: 27116334
    [Abstract] [Full Text] [Related]

  • 15. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
    Kirchberger MC, Hauschild A, Schuler G, Heinzerling L.
    Eur J Cancer; 2016 Sep 19; 65():182-4. PubMed ID: 27501507
    [Abstract] [Full Text] [Related]

  • 16. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM.
    Curr Oncol; 2018 Oct 19; 25(5):e403-e410. PubMed ID: 30464691
    [Abstract] [Full Text] [Related]

  • 17. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
    Amode R, Baroudjian B, Kowal A, Jebali M, Allayous C, Bagot M, Madjlessi N, Roux J, Viguier M, Basset Seguin N, Porcher R, Pagès C, Lebbé C.
    Melanoma Res; 2017 Apr 19; 27(2):110-115. PubMed ID: 27926587
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
    Bastiaannet E, Battisti N, Loh KP, de Glas N, Soto-Perez-de-Celis E, Baldini C, Kapiteijn E, Lichtman S.
    J Geriatr Oncol; 2019 May 19; 10(3):389-397. PubMed ID: 30025821
    [Abstract] [Full Text] [Related]

  • 19. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C, Khushalani NI, Zager JS.
    Expert Opin Biol Ther; 2016 Dec 19; 16(12):1491-1499. PubMed ID: 27602429
    [Abstract] [Full Text] [Related]

  • 20. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, Nagai K, Ishida Y, Nakamura Y, Furudate S, Yamamura K, Imafuku K, Yamamoto Y.
    J Dermatol Sci; 2018 Jan 19; 89(1):60-66. PubMed ID: 29079332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.